Department of Neurosurgery, People's Hospital of Deyang City, Sichuan Clinical Research Center for Neurological Diseases, Deyang; Co-innovation Center of Neuroregeneration, Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education; Department of Orthopedics, Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong University, Nantong, China.
Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113397. doi: 10.1016/j.intimp.2024.113397. Epub 2024 Oct 25.
Exosomes derived from primary chondrogenic stem/progenitor cells (CSPCs-EXOs) show promise in cartilage repair due to their immunomodulatory and regenerative properties. However, their specific therapeutic potential in osteoarthritis (OA), especially in modulating immune responses and enhancing chondrocyte function, requires further exploration. This study aims to clarify CSPCs-EXOs' effects on OA by investigating their role in chondrocyte proliferation, migration, inflammation inhibition, and cartilage regeneration.
A rat model of osteoarthritis was established using monosodium iodoacetate (MIA). CSPCs-EXOs were isolated and characterized before being administered to the OA rats. Comprehensive transcriptomic analysis was conducted to identify differentially expressed genes (DEGs) and signaling pathways influenced by CSPCs-EXOs. Histopathological evaluation of cartilage tissue, immunohistochemistry, and in vitro assays were performed to assess chondrocyte proliferation, migration, inflammation, and intracellular environmental changes.
CSPCs-EXOs treatment significantly reduced OA-induced cartilage damage, shown by improved histopathological features, increased chondrocyte proliferation, migration, and enhanced cartilage matrix integrity. CSPCs-EXOs uniquely modulated immune pathways and enhanced cellular repair, setting them apart from traditional treatments. Transcriptomic analysis revealed regulation of immune response, inflammation, oxidative stress, and DNA repair pathways. CSPCs-EXOs downregulated inflammatory cytokines (TNF, IL-17) and upregulated pathways for cellular proliferation, migration, and metabolism. They also altered splicing patterns of DNA repair enzymes, indicating a role in boosting repair mechanisms.
CSPCs-EXOs promote cartilage repair in osteoarthritis by modulating immune responses, inhibiting inflammation, and improving the intracellular environment. These findings emphasize their innovative therapeutic potential and offer key insights into their regenerative mechanisms, positioning CSPCs-EXOs as a promising strategy for OA treatment and a foundation for future clinical applications in cartilage tissue engineering and regenerative medicine.
源自原代软骨祖细胞(CSPCs-EXOs)的外泌体因其免疫调节和再生特性在软骨修复中具有广阔的应用前景。然而,其在骨关节炎(OA)中的特定治疗潜力,尤其是在调节免疫反应和增强软骨细胞功能方面,需要进一步探索。本研究旨在通过研究 CSPCs-EXOs 在软骨细胞增殖、迁移、炎症抑制和软骨再生中的作用,阐明 CSPCs-EXOs 对 OA 的影响。
采用碘乙酸单钠(MIA)建立大鼠 OA 模型。在将 CSPCs-EXOs 施用于 OA 大鼠之前,对其进行分离和表征。进行综合转录组分析,以鉴定受 CSPCs-EXOs 影响的差异表达基因(DEGs)和信号通路。对软骨组织进行组织病理学评估、免疫组织化学和体外检测,以评估软骨细胞增殖、迁移、炎症和细胞内环境变化。
CSPCs-EXOs 治疗可显著减轻 OA 诱导的软骨损伤,表现为改善的组织病理学特征、增加的软骨细胞增殖、迁移和增强的软骨基质完整性。CSPCs-EXOs 独特地调节免疫途径并增强细胞修复,使其与传统治疗方法有所区别。转录组分析显示免疫反应、炎症、氧化应激和 DNA 修复途径的调节。CSPCs-EXOs 下调炎症细胞因子(TNF、IL-17),上调细胞增殖、迁移和代谢途径。它们还改变了 DNA 修复酶的剪接模式,表明在增强修复机制方面发挥作用。
CSPCs-EXOs 通过调节免疫反应、抑制炎症和改善细胞内环境促进 OA 中的软骨修复。这些发现强调了其创新的治疗潜力,并为其再生机制提供了关键见解,使 CSPCs-EXOs 成为 OA 治疗的有前途的策略,并为软骨组织工程和再生医学中的未来临床应用奠定了基础。